Current Status of Accounting for Drug Production Processes in Uzbekistan and Directions for Improvement

This article examines the current state of accounting for drug production processes in the Republic of Uzbekistan and identifies key directions for its improvement in the context of modern economic reforms and the rapid development of the pharmaceutical industry. The relevance of the research is обусловлена the growing importance of ensuring transparency, efficiency, and reliability in accounting systems, particularly in strategically significant sectors such as pharmaceutical manufacturing, which directly impacts public health and national economic security.
The study analyzes the existing regulatory framework governing accounting practices in pharmaceutical enterprises, including national accounting standards and their alignment with international financial reporting standards (IFRS). Special attention is paid to the specific features of cost accounting in drug production, such as the complexity of technological processes, strict quality control requirements, multi-stage production cycles, and the necessity of tracking raw materials, semi-finished, and finished products. The paper highlights the challenges associated with allocating indirect costs, accounting for losses, waste, and by-products, as well as managing inventory in compliance with pharmaceutical standards.
The article proposes a set of recommendations aimed at improving accounting practices in drug production processes. These include the development of industry-specific accounting guidelines, внедрение современных цифровых решений, harmonization with international standards, and strengthening internal control mechanisms. Furthermore, the importance of professional training and continuous development of accounting personnel is emphasized as a critical factor for successful reform implementation.